Skip to content
Open access

Impact of hepatitis C viremia on overall survival and hepatic decompensation among patients with unresectable HCC receiving immunotherapy.

Sep 2026 · Clinical and Translational Gastroenterology · 0 citations
Medicine

Abstract

INTRODUCTION Hepatitis C (HCV) is associated with an immunosuppressive liver microenvironment, but whether HCV affects immune checkpoint inhibitor (ICI) outcomes in unresectable hepatocellular carcinoma (HCC) remains unknown.

Methods

We performed a single-center retrospective cohort study of patients with unresectable HCC treated with ICIs. In patients with a history of HCV, viremia was defined as a detectable viral load prior to immunotherapy. The primary outcome was overall survival (OS); secondary outcomes were real-world progression-free survival (PFS), time on treatment, and time to hepatic decompensation.

Results

Among 350 unresectable HCC patients treated with ICIs, 135 (39%) had a history of HCV, of which 37 (27%) were viremic. Viremia was not associated with OS (HR 0.88, 95% CI 0.53-1.44, p=0.600), but was associated with longer real-world PFS (HR 0.59, 95% CI 0.36-0.96, p=0.033) and longer time on treatment (HR 0.63, 95% CI 0.40-0.99, p=0.044). Compared to patients with non-HCV related unresectable HCC (n=215), viremic patients had longer real-world PFS (HR 0.65, 95% CI 0.44-0.97, p=0.037) but non-viremic patients did not (HR 0.87, 95% CI 0.66-1.17, p=0.359). Viremia was not associated with time to hepatic decompensation (HR 1.11, 95% CI 0.61-2.04, p=0.728), but in patients who survived at least one year without decompensating, viremia was associated with shorter time to decompensation (29.8 months vs. median not reached, log-rank p=0.010).

Conclusions

Viremia was not associated with OS among ICI-treated HCV patients with unresectable HCC, but was associated with longer real-world PFS and time on treatment. Further studies are needed to investigate these findings.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.